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Abstract The chemokine stromal-cell-derived factor-1K (SDF-
1K) chemoattracts lymphocytes and CD34+ haematopoietic
progenitors and is the ligand for CXCR4 (CXC chemokine
receptor 4), the main co-receptor for T-tropic HIV-1 strains.
SDF-1K was NH2-terminally cleaved to SDF-1K(3-68) by
dipeptidyl-peptidase IV (CD26/DPP IV), which is present in
blood in soluble and membrane-bound form. SDF-1K(3-68) lost
both lymphocyte chemotactic and CXCR4-signaling properties.
However, SDF-1K(3-68) still desensitized the SDF-1K(1-68)-
induced Ca2+ response. In contrast to CD26/DPP IV-processed
RANTES(3-68), SDF-1K(3-68) had diminished potency to
inhibit HIV-1 infection. Thus, CD26/DPP IV impairs the
inflammatory and haematopoietic potency of chemokines but
plays a dual role in AIDS.
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1. Introduction
Chemokines constitute a family of low molecular mass cy-
tokines with leukocyte chemotactic and activating properties.
Together with adhesion molecules, they play a crucial role in
lymphocyte homing and in leukocyte migration to in£amma-
tory sites. Depending on the position of the ¢rst cysteines,
chemokines are divided in CC, CXC, C or CX3C chemokine
subfamilies [1^3]. Chemokines interact with their target cells
through seven transmembrane spanning G-protein coupled
receptors [4]. For ¢ve CXC chemokine receptors (CXCR)
and ten CC chemokine receptors (CCR) the ligands have
been identi¢ed. For various candidate (‘orphan’) chemokine
receptors, the functional ligand has not yet been identi¢ed.
A number of NH2-terminally truncated chemokines have
been isolated from natural sources [5^10]. Depending on the
chemokine, such posttranslational processing leads to entirely
di¡erent biological e¡ects ranging from conversion into a chem-
otactic protein (e.g. platelet basic protein into neutrophil-
activating peptide-2) [5,6], over the increase of in£ammatory
activity in the case of interleukin-8 [11], to complete inactiva-
tion for the monocyte chemotactic proteins-1, -2 and -3
[10,12]. Recently, dipeptidyl-peptidase IV (DPP IV; EC
3.4.14.5) or the lymphocyte activation marker CD26 was
found to be responsible for the NH2-terminal truncation of
RANTES into RANTES(3-68) [13,14]. RANTES(3-68) was
inactive at physiological concentrations in chemotaxis and
signaling assays on monocytes [9,13,14], but proved to be a
CCR5-speci¢c ligand with anti-in£ammatory properties [9,13].
The CC chemokines MIP-1K (macrophage in£ammatory
protein-1K), MIP-1L and RANTES have been shown to in-
hibit HIV-1 infection in leukocytes [15] and the MIP/
RANTES receptor, i.e. CCR5, was found to be the major
co-receptor for M-tropic HIV-1 strains [16^20]. Surprisingly,
CD26/DPP IV-truncated RANTES turned out to be a more
potent inhibitor of M-tropic HIV-1 infection than intact
RANTES [14].
LESTR/fusin or CXCR4, which is the receptor for SDF-1,
has been shown to be the main co-receptor for T-tropic HIV-1
strains [21^23]. Mature SDF-1K isolated from natural sources
[24] contains a Pro at the penultimate position corresponding
to the consensus sequence for CD26/DPP IV-cleavage [25].
Since CD26/DPP IV is present in soluble form in plasma
and as a membrane-bound protease on a variety of cells, in-
cluding a subset of T lymphocytes, we investigated whether
SDF-1K is a substrate for CD26/DPP IV, and, if so, whether
SDF-1K truncation by CD26/DPP IV has any e¡ects on the
lymphocyte chemotactic and HIV-1-inhibitory properties of
SDF-1K.
2. Materials and methods
2.1. Reagents, cells and virus
Recombinant carrier-free human SDF-1K was obtained from R and
D Systems (Abingdon, UK). Soluble CD26/DPP IV (sCD26/DPP IV)
was puri¢ed to homogeneity from total seminal plasma by anion
exchange chromatography and a⁄nity chromatography on immobi-
lized adenosine deaminase [26]. The enzymatic activity was deter-
mined using the £uorogenic substrate Gly-Pro-4-methoxy-2-naphthyl-
amide.
SUP-T1 cells (American Type Culture Collection, Rockville, MD,
USA) were cultured in RPMI 1640 (Boehringer Ingelheim, Heidel-
berg, Germany) supplemented with 10% fetal calf serum (FCS). Hu-
man osteosarcoma (HOS) cells transfected with CD4 and CXCR4 [17]
were grown in DMEM with glutamax (Life Technologies, Paisley,
Scotland) and 10% FCS. Puromycin (1 Wg/ml; Sigma, St. Louis,
MO, USA) was added to the medium as a selection agent. Peripheral
blood mononuclear cells (PBMC) from healthy donors were puri¢ed
by Lymphoprep density gradient centrifugation (Nycomed, Oslo,
Norway) and stimulated for 3 days at 37‡C with 1 Wg/ml phytohae-
magglutinin (PHA, Sigma) as previously described [27]. The activated
cells (PHA-stimulated blasts) were washed three times with phos-
phate-bu¡ered saline (PBS) prior to use in the antiviral assays. The
T-tropic HIV-1 strain NL4.3 was obtained from the National Institute
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of Allergy and Infectious Disease, AIDS reagent program (Bethesda,
MD, USA).
2.2. Incubation of chemokines with CD26/DPP IV and detection
of proteolytic processing
A 1000 molar excess of SDF-1K was incubated for 18 h at 37‡C
with soluble CD26/DPP IV in 100 mM Tris/HCl pH 7.7. Chemokines
were separated from CD26/DPP IV by SDS-PAGE on a Tris/Tricine
gel system as previously described [28]. Proteins were electroblotted
on PVDF (polyvinylidene £uoride) membranes (Problott, Perkin El-
mer, Foster City, CA, USA) and stained with Coomassie brilliant blue
R250. After destaining, membranes were rinsed at least ¢ve times with
ultrapure water (Milli Q; Millipore, Bedford, MA, USA). To obtain
su⁄cient amounts of pure truncated SDF-1K for biological assays, 30
Wg of chemokine was treated with CD26/DPP IV and the cleavage
product was puri¢ed by C-8 RP-HPLC as previously described for
RANTES [14]. CD26/DPP IV-treated chemokines, puri¢ed by RP-
HPLC or excised from PVDF blots, were NH2-terminally sequenced
by Edman degradation on a pulsed liquid phase 477A/120A protein
sequencer (Perkin Elmer) using N-methylpiperidine as a coupling
base.
2.3. Chemotaxis assays
Intact or truncated SDF-1K were tested for their lymphocyte chem-
otactic potency on lymphocytic SUP-T1 cells (2 days after subculti-
vation) in a Boyden microchamber at 5U106 cells/ml using 5 Wm pore
size ¢bronectin-coated polycarbonate membranes. After 4 h incuba-
tion at 37‡C in the microchamber, the cells were ¢xed and stained
with Di¡-Quick staining solutions (Harleco, Gibbstown, NJ, USA)
and the cells that migrated through the membranes were counted
microscopically in 10 oil immersion ¢elds at 500-fold magni¢cation.
The chemotactic index (CI) of a sample (duplicates in each chamber)
was calculated as the number of cells that migrated to the sample over
the number of cells that migrated to control medium [28].
2.4. Detection of intracellular Ca2+ concentrations
Intracellular Ca2 concentrations ([Ca2]i) were determined as pre-
viously described [29]. Brie£y, CD4/CXCR4-transfected HOS cells
(107 cells/ml) were loaded in growth medium for 30 min at 37‡C
with 2.5 WM of the £uorescent dye fura-2 (Molecular Probes Europe
BV, Leiden, The Netherlands). The cells were washed with growth
medium and calcium bu¡er (HBSS with 1 mM Ca2 and 0.1%
FCS, bu¡ered with 10 mM HEPES/NaOH at pH 7.4) and diluted
to 106 cells/ml. Fura-2 £uorescence was measured at 510 nm in an
LS50B luminescence spectrophotometer (Perkin Elmer) upon excita-
tion at 340 and 380 nm. The [Ca2]i was calculated from the Gryn-
kiewicz equation [30]. The Kd used was 224 nM. To determine Rmax
and Rmin, the cells were lysed with 50 WM digitonin and subsequently
Ca2 was complexed with EGTA at pH 8.5. For desensitization ex-
periments, cells were ¢rst stimulated with intact or CD26/DPP IV-
truncated SDF-1K and 100 s later with intact SDF-1K at a concen-
tration (0.3 nM) that induced a signi¢cant increase in [Ca2]i after
prestimulation with bu¡er.
2.5. Antiviral activity assay
PHA-stimulated lymphoblasts were treated with varying concentra-
tions of intact or CD26/DPP IV-treated SDF-1K at the time of in-
fection with the T-tropic NL4.3 HIV-1 strain (105 pg of p24). After
1 h, non-adsorbed virus was removed by washing three times with
PBS and HIV-1-infected blasts were cultured in the presence of 25 U/
ml IL-2, as previously described [27]. At day 10, HIV-1 titers were
determined in the culture supernatant with a commercial p24 Ag
ELISA (duPont, Wilmington, DL, USA).
3. Results
3.1. CD26/DPP IV truncates intact SDF-1K into
SDF-1K(3-68)
Recombinant SDF-1K was treated overnight with sCD26/
DPP IV, separated from the protease by SDS-PAGE, blotted
on a PVDF membrane and Coomassie blue stained. Edman
degradation of the 7 kDa protein yielded the sequence
VSLSYR which corresponds to the NH2-terminal sequence
of SDF-1K(3-68), that is intact SDF-1K without the ¢rst
two amino acids Lys and Pro. Substantial amounts of SDF-
1K(3-68) were generated by incubating 30 Wg of intact SDF-1K
with sCD26/DPP IV. The obtained SDF-1K(3-68) was puri-
¢ed by C-8 RP-HPLC and the NH2-terminal sequence
(VSLSYR) was con¢rmed by Edman degradation. No intact
SDF-1K was recovered after CD26/DPP IV treatment and no
truncation of SDF-1K occurred in the absence of CD26/DPP
IV, indicating the speci¢city of the cleavage.
3.2. E¡ect of CD26/DPP IV on the lymphocyte chemotactic
and CXCR4-signaling capacity of SDF-1K
Intact and CD26/DPP IV-truncated SDF-1K were com-
pared in vitro for their ability to attract lymphocytic SUP-
T1 cells in the Boyden microchamber assay and for their
potency to signal (increase in [Ca2]i) through CXCR4 (Fig.
1). Intact SDF-1K was signi¢cantly chemotactic from 1 nM
onwards with a maximal chemotactic e¡ect at 10 nM. On
CXCR4 transfectants a clear increase in the [Ca2]i was al-
ready obtained with intact SDF-1K at 0.1 nM. In contrast,
SDF-1K(3-68) was inactive at concentrations up to 30 nM
both in the chemotaxis and Ca2 assay.
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Fig. 1. E¡ect of CD26/DPP IV-cleavage on the chemotactic and
Ca2-mobilizing activity of SDF-1K. Varying concentrations of in-
tact SDF-1K(1-68) (squares) and truncated SDF-1K(3-68) (triangles)
were compared for their lymphocyte chemotactic activity on SUP-
T1 cells in the Boyden microchamber (upper panel). Results repre-
sent the mean CI þ S.E.M. of four or more independent experi-
ments. Statistically signi¢cant di¡erence between the two SDF-1K
forms was calculated with the Student’s t-test (*, P6 0.1;
**, P6 0.05; ***, P6 0.01). SDF-1K(1-68) (squares) and truncated
SDF-1K(3-68) (triangles) were also compared for their potency to
induce an increase in the [Ca2]i (mean þ S.E.M. of three or more
independent experiments) in CD4/CXCR4-transfected HOS cells
(lower panel). The dotted line at 10 nM represents the detection
limit of the Ca2 assay.
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3.3. CD26/DPP IV-truncated SDF-1K(3-68) inhibits
lymphocyte signaling by intact SDF-1K
Ca2 responses towards 0.3 nM of SDF-1K(1-68) were com-
pletely desensitized by prestimulation of CXCR4 transfectants
with 1 nM SDF-1K(1-68), whereas with an equimolar concen-
tration about 50% desensitization of intact SDF-1K was ob-
tained (Fig. 2). Although CD26/DPP IV-truncated SDF-1K(3-
68) was inactive in the Ca2 assay at 30 nM, 10 nM of this
truncated chemokine led to a 50% reduction in the response
towards a subsequent challenge with intact SDF-1K (Fig. 2).
It must be concluded that although SDF-1K(3-68) failed to
signal through CXCR4, the molecule is still able to bind and
to desensitize for intact SDF-1K.
3.4. Inhibitory e¡ect of the CD26/DPP IV-truncated SDF-1K
on HIV-1 infection
Intact and CD26/DPP IV-truncated SDF-1K were com-
pared for their ability to inhibit infection of peripheral blood
mononuclear cells with the T-tropic HIV-1 strain NL4.3,
which uses CXCR4 as co-receptor (Fig. 3). NH2-terminal
processing of SDF-1K by CD26/DPP IV signi¢cantly dimin-
ished the anti-HIV-1 potency of the chemokine. For intact
SDF-1K, an IC50 value of 1.5 nM was obtained, while no
50% inhibition was reached with SDF-1K(3-68) at a concen-
tration up to 50 nM. Despite the 40-fold decrease in antiviral
activity compared to intact SDF-1K, SDF-1K(3-68) at 10 nM
still caused a 43% reduction in viral production.
4. Discussion
A number of NH2-terminally truncated CXC and CC chem-
okine forms have been isolated from cellular sources [5^10].
Most of these NH2-terminal modi¢cations signi¢cantly in-
crease or reduce the biological activity of the molecules.
Although the ¢rst reports date from almost 2 decades ago,
only little is known about the enzymes which are responsible
for the NH2-terminal processing of chemokines. Plasmin and
trypsin convert the connective tissue activating peptide III
into L-thromboglobulin which in turn is further processed
by chymotrypsin and cathepsin G into the CXC chemokine
neutrophil-activating peptide-2, a neutrophil chemoattractant
which interacts with CXCR2 [31^34]. Recently, the dipeptidyl-
peptidase CD26/DPP IV has been reported to be able to
process the CC chemokine RANTES into RANTES(3-68)
[13,14]. RANTES(3-68) is a chemotaxis inhibitor and has im-
paired signaling properties through CCR1 and CCR3, but not
through CCR5 [9,13,14]. Moreover, RANTES(3-68) is a more
potent inhibitor of HIV-1 infection than intact RANTES [14].
Another chemokine with a penultimate Pro at the NH2-
terminus, the consensus motif for potential CD26/DPP IV
substrates, is the lymphocyte chemotactic molecule SDF-1
[24]. SDF-1 is the ligand for CXCR4, the main co-receptor
for T-tropic HIV-1 strains [21^23]. Here, we report that
CD26/DPP IV cleaves the two NH2-terminal residues from
SDF-1K, selectively generating SDF-1K(3-68). Processing of
SDF-1K by CD26/DPP IV results in loss of lymphocyte chem-
otactic activity and signaling properties through CXCR4.
However, inactive SDF-1K(3-68) still desensitizes for SDF-
1K-induced Ca2 responses through CXCR4. In a report on
the solution structure of SDF-1, synthetic SDF-1 variants,
including SDF-1(3-67), have been used to investigate the in-
£uence of NH2-terminal truncation on the biological activity
of SDF-1 [35]. The data have led to a two-site model for SDF-
1 binding to CXCR4. The two receptor binding sites are sit-
uated in SDF-1(1-17). The region SDF-1(12-17) is thought to
initiate binding to CXCR4, and this docking step could facil-
itate access of the NH2-terminal residues to a more buried
receptor site. SDF-1(3-67) still interacts with CXCR4, but
with lower a⁄nity. The reduced binding a⁄nity probably ex-
plains why SDF-1K(3-68) is able to desensitize for Ca2 re-
sponses towards intact SDF-1K and also why we still ob-
served, albeit reduced, antiviral activity against T-tropic
strains in PBMC when SDF-1K was processed by CD26/
DPP IV.
The ¢ndings that CD26/DPP IV is able to process the NH2-
terminus of both RANTES [13,14] and SDF-1K with di¡er-
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Fig. 2. Desensitization of the SDF-1K-induced Ca2 response by
SDF-1K(1-68) and SDF-1K(3-68). CD4/CXCR4-transfected HOS
cells were prestimulated with bu¡er or varying concentrations of
CD26/DPP IV-treated SDF-1K(3-68) or SDF-1K(1-68). After 100 s,
cells were restimulated with 0.3 nM SDF-1K(1-68). Results represent
the mean þ S.E.M. of three or more independent experiments. The
dotted line at 10 nM represents the detection limit for the Ca2 as-
say.
Fig. 3. CD26/DPP IV diminishes the anti-HIV-1 activity of SDF-
1K. PHA-stimulated PBMCs were left untreated (black bar) or
treated with varying concentrations of intact SDF-1K (dashed bars)
or CD26/DPP IV-truncated SDF-1K(3-68) (open bars) at the time
of infection with the NL4.3 strain of HIV-1. Virus replication was
quanti¢ed by measuring the viral antigen p24 in a p24 ELISA. Re-
sults represent one representative experiment out of two.
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ential e¡ects on their anti-HIV-1 activity, brings novel insights
into the role of CD26/DPP IV in HIV-1 infection. Although
signi¢cantly lower numbers of CD26 memory cells have been
detected in HIV-infected persons [36], which can be explained
by the observation that CCR5 is expressed by CD26high T
cells [37], CD26/DPP IV remains present in plasma [36].
Thus, during all stages of the HIV disease, signi¢cant amounts
of active CD26/DPP IV are present. M-tropic CCR5 using
HIV-1 strains predominate during the asymptomatic phase.
Higher levels of CD26/DPP IV may therefore be bene¢cial
during this initial stage by increasing the anti-HIV-1 potency
of RANTES against M-tropic strains. However, at late stages
of HIV-1 infection, when T-tropic viruses are more frequently
isolated, CD26/DPP IV activity can promote infection with T-
tropic viruses due to the reduced antiviral activity of truncated
SDF-1(3-68). These ¢ndings may help to explain the con£ict-
ing results on the role of CD26/DPP IV in AIDS. However,
further studies on other chemokines which may be processed
by CD26/DPP IV (e.g. MIP-1L) are necessary to clarify this
issue.
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